Ivermectin, Vitamin D, and Emerging Therapies for Dengue: Clinical Evidence, Case Reports, and 2026 Pipeline Review

Abstract

Dengue virus infection lacks a specific approved antiviral. Supportive care remains the standard of management. This 2026 narrative review synthesizes evidence on repurposed agents, with detailed analysis of ivermectin (clinical trials and scarce case reports) and vitamin D (observational associations with severity, supplementation trials, and immunomodulatory mechanisms). While ivermectin accelerates NS1 clearance without proven clinical benefit, vitamin D deficiency correlates with increased severity in multiple studies, and high-dose supplementation has shown signals of reduced progression to severe dengue in small randomized trials. Emerging candidates such as mosnodenvir, VIS-513 monoclonal antibody, and EYU688 offer stronger developmental promise. Vitamin D represents a safe, inexpensive adjunctive option warranting larger confirmatory trials.

Keywords: ivermectin dengue treatment, vitamin D dengue, dengue vitamin D deficiency severity, repurposed drugs for dengue, dengue antiviral candidates 2026, NS1 clearance, case reports ivermectin dengue

1. Introduction

Dengue remains a leading mosquito-borne viral disease, with expanding geographic range driven by climate and urbanization. No specific antiviral is licensed. Management centers on early supportive care. Drug repurposing and micronutrient interventions continue to attract interest. This review updates the evidence on ivermectin, incorporates recent data on vitamin D status and supplementation, evaluates other repurposed agents, and ranks leading pipeline candidates as of August 2026.

2. Methods

Narrative synthesis of peer-reviewed literature, ClinicalTrials.gov, WHO ICTRP, and systematic reviews through August 2026. Emphasis placed on RCTs, observational severity associations, case reports/series, and preclinical-to-clinical translation for ivermectin, vitamin D, and novel antivirals.

3. Results

3.1 Standard of Care

WHO and CDC guidelines prioritize rest, careful fluid management (oral or intravenous crystalloids guided by hematocrit and clinical response), acetaminophen for fever and pain, and avoidance of NSAIDs such as ibuprofen or aspirin. Early detection of warning signs markedly reduces mortality.

3.2 Vitamin D in Dengue

Vitamin D (cholecalciferol) exhibits immunomodulatory and potential antiviral properties relevant to dengue pathogenesis.

  • Observational evidence: Multiple studies from Asia (Pakistan, India, Vietnam, Singapore) demonstrate that low serum 25-hydroxyvitamin D levels are associated with greater disease severity, including higher rates of dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), severe bleeding, and lower platelet counts. Deficiency is common among hospitalized patients. Some cohorts report inverse correlations between 25(OH)D and inflammatory markers.
  • Case series: A 2009 report of five patients treated with oral calcium plus vitamin D3 described improved clinical condition and shorter symptom duration.
  • Intervention trials:
    • A Pakistani RCT (n=124) using a single 200,000 IU dose found markedly lower progression to DHF (1.6% vs 27% in controls).
    • A Philippine double-blind RCT of daily cholecalciferol 800 IU reported shorter hospital stay, higher mean platelet counts, and reduced risk of progression to severe dengue (relative risk ≈0.19).
    • Larger Phase 2 trials (e.g., NCT06071481 in Bangladesh testing 200,000 IU and 400,000 IU single doses) are ongoing or recently completed to evaluate prevention of DHF/DSS.
  • Mechanisms: Vitamin D receptor (VDR) activation can reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1), limit viral replication in macrophages, and modulate endothelial responses. Synthetic VDR agonists have shown in-vitro anti-DENV activity.

Overall, vitamin D deficiency appears linked to worse outcomes, and supplementation is safe and inexpensive. Evidence quality is moderate; larger multicenter RCTs are still needed before routine recommendation.

3.3 Ivermectin: Trials and Case Reports

PubMed has indexed more than 30 research studies on ivermectin and dengue.

Ivermectin is often recognized – 2nd to penicillin – for having the greatest impact on human health. And its discovery won the Nobel Prize in 2015. Ivermectin has an increasing list of indications due to its antiviral and anti-inflammatory properties, and is included on the WHO’s Model List of Essential Medicines.

Several studies (2020) reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and COVID 19 virus.

Ivermectin inhibits the replication of all 4 DENV serotypes in vitro (Clinical Infectious Diseases 2021).

A 2021 randomized controlled study by Suputtamongkol and colleagues report the findings of a combined phase II and III randomized, double-blind, placebo-controlled trial to test the efficacy of ivermectin as an antiviral drug for dengue. 

The trials enrolled a total of 238 patients with dengue—108 in phase 2 and 130 in phase 3 trials. The phase II trial compared 2- and 3-day courses of a once-daily 0.4 mg/kg dose of ivermectin with 3 days of placebo to identify an optimal dosing regimen. The phase III trial followed up on these findings and compared 3-day, once-daily ivermectin dosing with placebo. The primary endpoints were time to virological clearance in the phase II trial and time to fever clearance in the phase III trial. The authors found that, in both trials, time to DENV NS1 antigen clearance was significantly shorter in patients who received doses for 3 days with ivermectin compared with placebo. However, the primary endpoints for both phases II and III trials were not met.

The combined Phase 2/3 Thai RCT (n=203 adults) of 400 µg/kg daily for three days demonstrated accelerated NS1 antigen clearance (median 71.5 vs 95.8 hours) and higher rates of undetectable NS1 at discharge, without differences in viremia, fever duration, or clinical severity. Pediatric pharmacokinetic data exist but do not alter the efficacy picture. 

According to the review of this study:

Ivermectin has been shown in experimental models to inhibit both DENV protease as well as translocation of viral proteins into the host nucleus. However, the exact mechanisms have not been defined. Consequently, it is possible that the ivermectin concentrations needed to elicit these inhibitory effects exceeded what can be achieved pharmacokinetically, despite a relative high dose in the phase II and III trials. Thus, while drug repurposing theoretically offers a rapid pathway for discovering new antiviral indications, matching in vitro investigations with drug pharmacokinetics is critical to avoid disappointment during clinical trials.

The possibility that a pharmacokinetic explanation underpinned the current lack of efficacy of ivermectin could be clarified in an ongoing trial of this drug in pediatric patients with dengue (NCT03432442). This trial is exploring an even higher dose (600 μg/kg) of ivermectin as an anti-dengue drug. The final word on repurposing ivermectin as an anti-dengue drug has thus yet to be written.

A 2023 Mexican study by Palacios-Rápalo and colleaques, demonstrated that Ivermectin (IVM) and Atorvastatin (ATV) combination reduced Dengue infection both in vitro and in vivo, suggesting a potential anti-dengue therapy that could be further tested clinically.

Dedicated peer-reviewed individual case reports of successful ivermectin monotherapy for dengue remain extremely scarce; most literature consists of the RCTs above. High-dose toxicity reports exist but are unrelated to therapeutic benefit.

3.4 Other Repurposed Agents

Chloroquine, celgosivir, balapiravir, and lovastatin have failed to show consistent clinical benefit in RCTs. Doxycycline (sometimes combined with Carica papaya leaf extract) has weak signals for platelet recovery in small studies. Host-directed agents (dexamethasone, anakinra, baricitinib, N-acetylcysteine) are being tested in adaptive trials for moderate-to-severe disease.

3.5 Leading Developmental Candidates (2026 Ranking)

  1. Mosnodenvir (JNJ-1802) – Strongest human antiviral signals in controlled infection models; development paused for strategic reasons.
  2. VIS-513 / Dengushield monoclonal antibody – Advanced clinical stage (Phase 2 completed, Phase 3 ongoing/planned).
  3. EYU688 (Novartis NS4B inhibitor) – Active Phase 2a treatment trial in early symptomatic patients.

3.6 Nature's Shield: Plant Oils That Keep Mosquitoes at Bay

Consistent, natural mosquito prevention methods are your best defense against these disease-carrying invaders. A study published in the journal Molecules unveiled the ability of certain plant essential oils to effectively repel mosquitoes, offering a natural alternative to synthetic products. (6)

Researchers examined oils from five aromatic plants: Lantana camara, Schinus terebinthifolia, Callistemon viminalis, Helichrysum odoratissimum and Hyptis suaveolens. These were tested against three mosquito species known for spreading diseases like dengue, malaria and West Nile virus.

The standout performers? Lantana camara and Schinus terebinthifolia (Brazillian pepper) oils showed exceptional repellent properties, rivaling the effectiveness of DEET, the toxic synthetic repellent.7

Interestingly, different mosquito species reacted differently to the oils, with Culex quinquefasciatus (a carrier of West Nile virus) being the most susceptible to the repellents, followed by Aedes aegypti (dengue vector), while Anopheles gambiae (malaria vector) showed more resistance.

3.7 The Science Behind the Scent

You might wonder what makes these plant oils so effective against mosquitoes. The secret lies in their complex chemical composition. For instance, the Lantana camara oil, which showed the highest repellency, contains a mix of compounds including trans-β-caryophyllene, sabinene and 1,8-cineole. These components work together to create a potent mosquito deterrent.

The Schinus terebinthifolia oil, another top performer, boasts a blend of α-pinene, limonene and α-phellandrene. These natural chemicals likely interfere with the mosquitoes' sensory receptors, making it difficult for them to locate their human targets. What's particularly exciting is the longevity of the repellent effect. In some cases, the oils provided protection for up to 180 minutes at higher concentrations.

This extended protection period rivals that of many commercial repellents, suggesting that these natural alternatives are just as practical for everyday use. Moreover, the study found that these oils not only repel adult mosquitoes but also deter females from laying eggs in treated water sources, breaking the mosquito life cycle at multiple points.8

While the study used pure essential oils, it's important to note that these should be properly diluted before application to the skin. You might consider looking for natural repellent products that incorporate these oils, or work with a qualified aromatherapist to create a safe, effective blend.

Beyond personal use, these findings open up exciting possibilities for wider mosquito control strategies, like mosquito traps infused with these natural repellents or public spaces protected by the subtle scent of these plants.

3.8 More Traditional Essential Oils as Mosquito Repellents

Another study uncovered the potential of two plants, Citrus macroptera (locally known as Hatkora) and Homalomena aromatica (known as Anchiri), as effective mosquito repellents.9

These plants have been used traditionally by the inhabitants of Mizoram state in India, and now science is backing up their ancestral wisdom. The essential oils extracted from the fruit peel of C. macroptera and the rhizomes of H. aromatica have shown promising results against Aedes aegypti mosquitoes.

The study revealed that H. aromatica oil provided protection for up to 6.16 hours, while C. macroptera oil lasted for 5.16 hours. Compare this to the commonly used DEET, which offers about eight hours of protection.

When these two oils were combined in a 1:1 ratio, they provided protection for 6.33 hours. This natural blend not only repels mosquitoes effectively but also comes with additional benefits, thanks to the presence of limonene, which has antioxidant, anti-inflammatory and neuroprotective properties.

The major components found in both oils are linalool, limonene, terpinen-4-ol and α-terpineol. These compounds interact with the odorant-binding proteins of mosquitoes, essentially confusing their sensory system and making it harder for them to locate you as a potential meal. The researchers conducted molecular docking studies to understand this interaction better.

They found that linalool, which is present in high quantities in H. aromatica oil, had the highest binding energy against the mosquito's odorant-binding protein. This explains why H. aromatica oil showed longer-lasting repellent activity. While limonene had the lowest binding energy, its presence in the oil mixture provides a pleasant scent and additional health benefits, making the blend more appealing for regular use. (10)

3.9 The Power of Environmental Management

One of the most effective ways to shield yourself from mosquito-borne threats is through environmental management. This approach focuses on eliminating mosquito breeding sites and creating an inhospitable environment for these pests. Start by removing standing water around your property, as this is where mosquitoes lay their eggs.

Regularly empty and clean birdbaths, pet water bowls and any containers that collect rainwater. Ensure your gutters are clear and properly draining to prevent water accumulation. Maintain your lawn and garden by keeping grass short and removing excess vegetation where mosquitoes might rest. Consider planting mosquito-repelling plants like citronella grass, marigolds or lavender around your outdoor living areas.

These natural deterrents help create a mosquito-free zone without the use of chemical sprays. You can also install or repair screens on windows and doors to keep mosquitoes out of your home.

In addition, wear light-colored, loose-fitting long sleeves and pants when you're outdoors, especially during dawn and dusk when mosquitoes are most active. These simple clothing choices significantly reduce the amount of exposed skin for mosquitoes to target.

You can also invite nature's mosquito control experts to your yard. Bats are voracious mosquito eaters, capable of consuming up to 1,000 mosquitoes in a single hour.11 Install bat houses in your yard to provide these beneficial creatures with a home. Not only will you be reducing the mosquito population, but you'll also be supporting local wildlife.

Remember, conventional mosquito repellents often contain DEET, a chemical that I've long warned about due to its potential neurotoxic effects. Instead, try natural alternatives like citronella, lemon eucalyptus oil or neem oil. These plant-based repellents are highly effective when used correctly. By embracing these natural methods, you're not only protecting yourself but also contributing to the overall reduction of mosquito populations in your community.

3.10 These Other Natural Remedies May Help With Dengue Recovery

While there are no medications that can cure dengue fever, you can turn to certain foods, herbal remedies and supplements to help naturally strengthen your immune system, increase platelet count and manage symptoms to help facilitate the healing process.

Certain natural remedies have antiviral properties that may help with dengue fever recovery. These include:
  1. Carica papaya (Caricaceae) — A 2024 study published in the Asian Plant Research Journal (36) says that leaf extracts of this exotic plant, native to Sri Lanka, can "neutralize plasma with the dengue virus, reduce platelet aggregation, and increase the production of the enzyme ALOX12, which promotes platelet production" in dengue patients. An earlier study, published in the Sri Lankan Journal of Infectious Diseases in 2021,37 found that C. papaya extracts may help inhibit DENV-1 infections, suggesting "the potential of C. papaya leaf extract for future development of antiviral drugs against DENV-1."
  2. Euphorbia hirta (Euphorbiaceae) — Also known as "asthma plant," this branched herb only grows up to 70 centimeters high but shows promising potential with its antiviral properties. One analysis published in 2022 (38) notes that clinical investigations of E. hirta among dengue patients ages 30 to 35 years old found that supplementing with this herb helped reduce flu-like symptoms by approximately 70%. According to the study authors: (39) "The in vitro analysis of the ethanolic extract of the plant showed remarkable inhibition of plaque formation up to 85% and 34.7% against DENV-1 and DENV-2, respectively." In the Philippines, where more dengue cases are being reported this year compared to 2023, (40) a water decoction made with E. hirta leaves is used to help recover from this condition. (41)
  3. Velvetleaf (Cissampelos pareira) — Native to Sri Lanka, India and the Amazon forest, velvetleaf is a flowering plant that belongs to the Menispermaceae family. A study (42) highlights it as one of the botanicals that have shown promise in inhibiting DENV replication, noting that: "Almost all parts … like aerial parts, roots, and stem barks as well as the whole plants show protective effects against DENV, which are not restricted to DENV-2 or DENV-1 only, but also against type 3 (DENV-3) and type 4 (DENV-4)."
  4. Elderberry (Sambucus nigra L.) — Belonging to the family Adoxaceae, elderberry is rich in flavonoids, which are responsible for its antiviral activity. Aside from the extract, elder flowers and leaves were found to have antiviral effects against the DENV-2 strain, at concentrations of 400 micrograms/milliliter (ug/ml).43
  5. Garlic (Allium sativum) — Garlic has been widely praised for its antibacterial, antioxidant, anticarcinogenic and other therapeutic properties. One study notes that the organosulfur compounds in this herb, particularly diallyl disulfide (DADS), diallyl sulfide (DAS) and alliin, may significantly inhibit the inflammatory cytokines in DENV-2 infection.44

3.11 Nutrition Matters — Boost Your Intake of These Nutrients

Getting enough rest, staying hydrated and consuming a healthy diet are all essential strategies if you’re recovering from a viral disease like dengue fever. During this time, it’s particularly important to get sufficient amounts of healthy nutrients, as some may particularly help speed up the healing process.

A 2021 literature review published in the American Journal of Tropical Medicine and Hygiene (45) highlights studies from several countries on how supplementing with certain micronutrients may "offer hypothetical benefits to dengue patients via numerous potential mechanisms, including modulation of the host immune response." Some of the nutrients mentioned include:
  • Vitamin C — Indian researchers46 found that patients who were given supplemental vitamin C not only had a shorter hospital stay, but also had higher platelet counts than those who did not take the supplement.
  • Vitamin D — see above.
  • Vitamin E — Researchers from Sri Lanka48 noted that dengue patients who received vitamin E supplements showed "improvements in various clinical and hematological parameters, including significantly higher subsequent platelet counts among patients admitted for thrombocytopenia."
  • Zinc — A study49 conducted in Thailand found that supplementing with zinc led to a shorter duration of hospitalization among children infected with dengue.
If you consume a healthy, well-balanced diet loaded with whole foods including fruits and vegetables, you’ll have no shortage of these nutrients. For example, kiwi, dragon fruit and papaya are rich in vitamins A, C, E and potassium, all of which may help promote immunity and increase your platelet count naturally.50 As for vitamin D, the best way to boost your levels is to get regular sun exposure as close to solar noon as possible.


4. Discussion

Vitamin D stands out among micronutrients and repurposed options because of consistent observational links to severity and encouraging (though still limited) intervention data. Its safety profile and low cost make it an attractive adjunct while definitive trials mature. Ivermectin’s NS1 effect has not translated into clinical gains at tested doses. Novel direct-acting agents remain the highest long-term priority. Limitations include heterogeneous study designs, variable vitamin D dosing regimens, and the challenge of intervening early enough in the disease course.

5. Conclusion

Supportive care is the only proven therapy for dengue in 2026. Vitamin D deficiency is associated with greater severity, and high-dose supplementation shows preliminary signals of benefit that merit larger confirmation. Ivermectin accelerates NS1 clearance without clinical efficacy, and published case reports are rare. Pipeline candidates (mosnodenvir, VIS-513, EYU688) represent the most promising path to specific therapy. Clinicians may consider assessing and correcting vitamin D status as a low-risk supportive measure while awaiting stronger evidence, but should avoid unproven off-label antivirals outside trials.


Sources and References

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Diagnosis and treatment of dengue require professional medical care.

Comments

Post a Comment

Popular posts from this blog

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: August 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection indic...
Read more

How Many Years Can a Healthy Lifestyle Add to Your Life? The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs (2026)

Image
Short answer: A healthy lifestyle may add years to life—and potentially a decade or more in some populations—but there is no scientifically valid number that applies to everyone. The strongest evidence suggests that the biggest gains come from a combination of not smoking, regular physical activity, a high-quality diet, maintaining a healthy body weight, and controlling major cardiovascular and metabolic risk factors . One influential U.S. analysis estimated that people who followed five low-risk lifestyle factors at age 50 had a projected life expectancy about 14 years longer for women and 12 years longer for men than people following none of those factors. However, this was a prospective observational analysis combined with life-table modelling—not a randomized trial proving that each person will live exactly 12–14 years longer. That distinction matters. It is tempting to interpret longevity studies as if they were a prescription for an extra number of years: exercise gi...
Read more

Testosterone, Men's Health & Healthy Aging: Low T, Testosterone Replacement and the Science of Anti-Aging

Image
Testosterone is one of the most important hormones in male health. It influences sexual function, muscle mass, bone health, red-blood-cell production, body composition and aspects of mood and energy. Testosterone levels also tend to decline as men age, creating growing interest in testosterone testing, testosterone replacement therapy (TRT), men's health optimization and longevity. Interest in testosterone treatment is also increasing again. New 2026 data from Epic Research show that testosterone prescribing rates in the United States have begun rising again after nearly a decade of decline. The trend is important because it suggests a renewed clinical and consumer focus on testosterone, men's health and hormonal aging—but a rise in prescribing does not itself prove that testosterone therapy is appropriate for every man. The central question remains: Does a man have clinically meaningful testosterone deficiency, what is causing it, and is testosterone replacement lik...
Read more

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity

Image
By Dr. Frank Yap, MD  |  Originally published April 2026  |  Fully updated August 26, 2026 for the FDA's July 2026 compounding committee vote Quick Answer As of August 2026, GLP-1 receptor agonists (semaglutide, tirzepatide) remain the only peptides in this guide with full FDA approval. On July 23–24, 2026, an FDA advisory committee (PCAC) recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list of substances compounding pharmacies may use — but that vote is non-binding, and none of the six is lawful to compound yet; formal rulemaking is expected to take 12–24 months. Separately, AOD-9604 failed its pivotal human obesity trial back in 2007. The best human evidence among the non-GLP-1 peptides here belongs to topical GHK-Cu (skin) and Selank (anxiety); the weakest belongs to BPC-157 and TB-500 (mostly animal data). Any protocol should run through a licensed physician — not a gray-market vendor. Medical & regu...
Read more

GLP-1 Drugs, Vitamin B1 and Wernicke Encephalopathy: What Happens When Weight Loss Goes Too Far?

Image
GLP-1 drugs can be highly effective for weight loss, but extreme appetite suppression, persistent nausea or vomiting, and very rapid weight loss can create a nutritional problem that is easy to overlook. One of the most serious possibilities is thiamine (vitamin B1) deficiency leading to Wernicke encephalopathy , a neurological emergency. Recent case reports, a 2025 pharmacovigilance analysis and a 2026 systematic review have raised a safety signal involving semaglutide, tirzepatide and other GLP-1-based therapies . The evidence remains limited and does not establish that GLP-1 drugs directly cause Wernicke encephalopathy in most users. Instead, the leading concern is an indirect pathway involving markedly reduced food intake, gastrointestinal intolerance, nutritional depletion and rapid weight loss . ( Gras et al., 2025 ; Goldman et al., 2026 ; Bidesie & Oudman, 2026 .) Key takeaway: The concern is not that everyone taking a GLP-1 medication ...
Read more

Preventive Medicine & Longevity Science (2026)

Image
An evidence-based guide to reducing chronic disease risk, extending healthspan, and understanding what truly works — beyond hype, supplements, and shortcuts. This page serves as the central hub for OneDayMD’s coverage of preventive medicine, cancer prevention, cardiometabolic health, and longevity science, grounded in epidemiology, clinical trials, and systems biology. What This Hub Covers (Quick Overview) This hub explains: What preventive medicine actually means in modern clinical science The difference between lifespan and healthspan Which interventions reduce disease risk with high-quality evidence Where longevity science is promising — and where it becomes speculation How lifestyle, medications, and emerging tools interact over decades It is designed for readers who want risk reduction, not biohacking fantasy . Executive Summary Preventive medicine focuses on reducing the probability of disease before it occurs , rather than treating pathology after it is established. Longevity ...
Read more

9 Best Berberine Supplements (2026 Review): Evidence, Dosage & New EU Safety Data

Image
By Dr Frank Yap, MD | Medically reviewed by the One Day MD Editorial Team | Last updated: August 2026 | Original publication: March 2023 Quick Answer A 2024–2025 meta-analysis of 50 RCTs (4,150 patients) confirms berberine modestly but reliably lowers fasting glucose, HbA1c, LDL cholesterol and inflammatory markers in type 2 diabetes and metabolic syndrome — solid, Tier 1a evidence. It is not "nature's Ozempic." Semaglutide produces roughly 10–15%+ body-weight loss in trials; berberine averages only about 2–4 lb a month. The mechanisms and effect sizes aren't comparable. Typical dosing is 500 mg, 2–3x daily with meals (1,000–1,500 mg/day). Bioavailability — not the milligram number on the label — is the biggest real difference between brands. New in 2026: A draft EU/UK scientific opinion (EFSA/COT, March 2026) flagged in-vitro genotoxicity signals, confirmed the CYP3A4 drug-interaction risk, and stated that regulators cannot yet establish a formal "...
Read more

NAC vs NAD vs NR vs NMN vs Niacin: What Are the Differences?

Image
By the One Day MD Editorial Team  |  Originally published September 2020  |  Last updated and medically fact-checked: August 2026 NAD, NAD+, NADH, NR, NMN, niacin, niacinamide, and NAC — these overlapping names cause constant confusion, and understandably so. Some are simply different names for the same molecule. Others are metabolic precursors that your body converts, step by step, into NAD+. One of them, NAC, isn't related to NAD+ metabolism at all. This guide breaks down what each compound actually does, how the human evidence stacks up as of 2026, and where the real safety trade-offs lie — including the January 2026 head-to-head human trial that finally pitted NR against NMN directly, and the FDA's 2025 reversal on NMN's legal status. Quick Answer NAD+ is the coenzyme your cells actually need for energy production and DNA repair, and it can't be taken as an oral supplement because it's too large a molecule to survive digestion intact. NR, NMN, n...
Read more

Ivermectin for Parkinson’s and Dementia: Analyzing the Neuroprotective Molecular Evidence and Clinical Case Reports (2026)

Image
Scientific Review & Regulatory Audit by the Clinical Editorial Team The therapeutic paradigm for progressive neurodegenerative disorders like Parkinson’s disease (PD) and various forms of dementia faces a critical bottleneck. Standard pharmacology, primarily anchored by levodopa (L-DOPA) for Parkinson’s and acetylcholinesterase inhibitors for dementia, remains strictly symptomatic. These options frequently suffer from diminishing efficacy and significant side-effect profiles like L-DOPA-induced dyskinesia over long-term use. Consequently, the pharmaceutical community has focused heavily on drug repurposing—identifying established, safety-vetted compounds capable of crossing pathways to modify disease progression. An unexpected frontline candidate emerging in this space is ivermectin. Traditionally classified as a broad-spectrum antiparasitic agent, a surge of preclinical studies between 2020 and 2024 has unveiled its complex, multi-targeted pharmacodynamics within the mam...
Read more

Why Keto Can Dramatically Raise LDL While Triglycerides Fall: The Lean Mass Hyper-Responder Phenomenon

Image
Why does LDL cholesterol sometimes rise dramatically on a ketogenic diet while triglycerides fall and HDL cholesterol rises? This is one of the most intriguing and controversial lipid responses associated with very-low-carbohydrate diets. For many people, a ketogenic diet produces a relatively modest change in LDL cholesterol. But a subset—particularly some lean individuals—can experience a much larger increase, occasionally reaching LDL-C levels above 300, 400, or even 500 mg/dL. At the same time, triglycerides may fall dramatically and HDL-C may rise. LDL-C ↑↑↑ Triglycerides ↓↓↓ HDL-C ↑ This combination is commonly referred to in the research literature as the Lean Mass Hyper-Responder (LMHR) phenotype. The phenomenon is important because it challenges the assumption that LDL and triglycerides must always move together. It also raises a difficult clinical question: what does dramatically elevated LDL mean when the individual otherwise appears metabolically healthy?...
Read more